Safety Alerts & Recalls
Search all Safety Alerts & Recalls
Latest Alerts
Statin Benefits Still Outweigh New Safety Information
A study published today in the medical journal "The Lancet" has reported that statins, a class of medicine used to treat high cholesterol, may be associated with a slightly increased risk of developing diabetes. Researchers who conducted the study found an extra case of diabetes for every 255 patients treated with a statin after four years - a significant finding - but still substantially lower than the five cardiovascular events these statins were found to prevent in the same group.
Statins are a class of cholesterol-lowering medications that include atorvastatin (Lipitor), fluvastatin (Lescol, Lescol XL), lovastatin (Altoprev, Mevacor), pitavastatin (Livalo), pravastatin (Pravachol), rosuvastatin (Crestor), and simvastatin (Zocor). Statins are also included in several combination products including Advicor, Caduet, Simcor, and Vytorin.
For more information, please visit:
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2809%2961965-6/fulltext
Learn More
The FDA Requires a Risk Management Program for Erythropoiesis-Stimulating Agents (ESAs)
The FDA is requiring all drugs called Erythropoiesis-Stimulating Agents (ESAs) to be prescribed and used under a risk management program, known as a risk evaluation and mitigation strategy (REMS), to ensure the safe use of these drugs. The ESAs that are part of the REMS are marketed under the names EPOGEN, PROCRIT, and ARANESP. The FDA required the manufacturers of these products to develop a risk management program because studies show that ESAs can increase the risk of tumor growth and shorten survival in patients with cancer who use these products. Studies also show that ESAs can increase the risk of heart attack, heart failure, stroke or blood clots in patients who use these drugs for other conditions.
As part of the REMS, a Medication Guide explaining the risks and benefits of ESAs must be provided to all patients receiving EPOGEN, PROCRIT, or ARANESP. In addition to the Medication Guide, the ESA APPRISE (Assisting Providers and Cancer Patients with Risk Information for the Safe use of ESAs) Oncology program will provide special training to healthcare professionals about the use of ESAs in patients with cancer.
For more information, please visit:
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200297.htm
Learn More